Calvo-Ortega Juan-Francisco, Hermida-López Marcelino
Oncología Radioterápica, Hospital Quirónsalud Barcelona, Barcelona, Spain.
Oncología Radioterápica, Hospital Quirónsalud Málaga, Malaga, Spain.
Rep Pract Oncol Radiother. 2023 Aug 28;28(4):529-540. doi: 10.5603/RPOR.a2023.0060. eCollection 2023.
The purpose was to validate the PRIMO Monte Carlo software to be used during the commissioning of a treatment planning system (TPS).
The Acuros XB v. 16.1 algorithm of the Eclipse was configured for 6 MV and 6 MV flattening-filter-free (FFF) photon beams, from a TrueBeam linac equipped with a high-definition 120-leaf multileaf collimator (MLC). PRIMO v. 0.3.64.1814 software was used with the phase space files provided by Varian and benchmarked against the reference dosimetry dataset published by the Imaging and Radiation Oncology Core-Houston (IROC-H). Thirty Eclipse clinical intensity-modulated radiation therapy (IMRT)/volumetric modulated arc therapy (VMAT) plans were verified in three ways: 1) using the PTW Octavius 4D (O4D) system; 2) the Varian Portal Dosimetry system and 3) the PRIMO software. Clinical validation of PRIMO was completed by comparing the simulated dose distributions on the O4D phantom against dose measurements for these 30 clinical plans. Agreement evaluations were performed using a 3% global/2 mm gamma index analysis.
PRIMO simulations agreed with the benchmark IROC-H data within 2.0% for both energies. Gamma passing rates (GPRs) from the 30 clinical plan verifications were (6 MV/6MV FFF): 99.4% ± 0.5%/99.9% ± 0.1%, 99.8% ± 0.4%/98.9% ± 1.4%, 99.7% ± 0.4%/99.7% ± 0.4%, for the 1), 2) and 3) verification methods, respectively. Agreement between PRIMO simulations on the O4D phantom and 3D dose measurements resulted in GPRs of 97.9% ± 2.4%/99.7% ± 0.4%.
The PRIMO software is a valuable tool for dosimetric verification of clinical plans during the commissioning of the primary TPS.
目的是验证在治疗计划系统（TPS）调试期间使用的PRIMO蒙特卡罗软件。
Eclipse的Acuros XB v. 16.1算法针对配备高清120叶多叶准直器（MLC）的TrueBeam直线加速器的6 MV和6 MV无 flattening-filter（FFF）光子束进行配置。使用PRIMO v. 0.3.64.1814软件和Varian提供的相空间文件，并与休斯顿影像与放射肿瘤学核心（IROC-H）发布的参考剂量学数据集进行基准测试。通过三种方式验证了30个Eclipse临床调强放射治疗（IMRT）/容积调强弧形治疗（VMAT）计划：1）使用PTW Octavius 4D（O4D）系统；2）Varian门静脉剂量测定系统；3）PRIMO软件。通过将O4D体模上的模拟剂量分布与这30个临床计划的剂量测量结果进行比较，完成了PRIMO的临床验证。使用3%全局/2 mm伽马指数分析进行一致性评估。
两种能量下，PRIMO模拟结果与基准IROC-H数据的一致性均在2.0%以内。30个临床计划验证的伽马通过率（GPRs）（6 MV/6MV FFF）分别为：1）验证方法为99.4%±0.5%/99.9%±0.1%，2）验证方法为99.8%±0.4%/98.9%±1.4%，3）验证方法为99.7%±0.4%/99.7%±0.4%。O4D体模上的PRIMO模拟结果与3D剂量测量结果之间的一致性导致GPRs为97.9%±2.4%/99.7%±0.4%。
PRIMO软件是在主TPS调试期间对临床计划进行剂量验证的有价值工具。
